Aspartate carbamoyltransferase catalyses one of the first reactions leading to the biosynthesis of pyrimidines, the transcarbamoylation of L-aspartic acid by carbamoyl phosphate to form carbamoylaspartate. In bacteria, the enzyme occupies a central position in the metabolic control of pyrimidine biosynthesis. The effectiveness of the feedback mechanism in regulating the synthesis of pyrimidines is due to the sensitivity of aspartate carbamoyltransferase to one of the end products of the pathway, CTP. The native enzyme may be separated into two types of sub-units: the larger, in which the catalytic activity resides, and a second, which possesses the regulatory sites (Gerhart & Pardee, 1962 , 1963 , 1964 Gerhart & Schachman, 1965) . These studies have established the allosteric nature of Escherichia coli aspartate carbamoyltransferase.
Aspartate carbamoyltransferase from lettuce (Neumann & Jones, 1964) , Pseudmonas (Neumann & Jones, 1964) , erythrocytes (Curci & Donachie, 1964) and mammalian systems (Bresnick & Hitchings, 1961; Bresnick, 1963) , however, does not behave in this manner. End-product inhibition is not manifested by CTP, but by other pyrimidine derivatives and only at high concentrations of both inhibitor and substrate. The enzyme has been partially purified from rat liver and some of its characteristics have been determined. The results which are presented below establish clearly the fundamental dissimilarity between the Escherichia coli and liver enzymes.
EXPERIMENTAL
Animals. Male rats, approx. 175-200g., were obtained from the Cheek-Jones Co., Houston, Texas, U.S.A., and were allowed free access to both food and water. The rats were killed by bleeding after aortic transection, the livers were removed, washed in cold 0.9% NaCl, and homogenized in cold 0-25m-sucrose at 40 (1:4, w/v Hydroxyapatite was prepared by the method of Tiselius, Hjertenend & Levin (1956) as modified by Myazawa & Thomas (1965) . Enzyme asmays. Three methods were employed in the assay of liver aspartate-carbamoyltransferase activity. Procedure 1. The enzyme was incubated at 370 for 15 min. in a total volume of 1-5 ml. with 5mM-L-aspartic acid, 0-7mM-carbamoyl phosphate and 0 2M-tris buffer, pH9*2. At the end of the incubation, the enzymic reaction was stopped by the addition of 0*2 ml. of 4N-HC104. The reaction tubes were placed in an ice bath for 5min. to coagulate the denatured proteins, which were then removed by centrifugation. The carbamoylaspartate was colorimetrically determined in a portion of the deproteinized material by the method of Koritz & Cohen (1954) as modified by Gerhart & Pardee (1962) . The colorimetric assay cannot be employed with high concentrations of thiol groups because of marked inhibition of colour development.
Procedure 2. Enzymic activity was ascertained by a radioactive assay in which DL-[3-14C]aspartate was utilized as substrate (Bresnick, 1965 2-4,umoles (0.3,uc) ; L-aspartate, 5mM; 0-2M-tris buffer, pH9-2, to 1-5ml. At the end of the incubation, 0-5ml. of 4N-HCI was added to stop the reaction, a portion was plated on planchets and was dried in an oven for 20min. The radioactivity was then estimated in a NuclearChicago gas-flow end-window counter at an efficiency of 25%.
The protein concentration of the enzymic extracts was estimated by the method of Lowry, Rosebrough, Farr & Randall (1951) with bovine serum albumin as the reference standard. The protein eluted from the Sephadex G-200 and hydroxyapatite columns was monitored by ultraviolet absorption at 240 and 280m,u.
RESULTS
Purification of aspartate carbamoyltransferase Aspartate carbamoyltransferase activity was concentrated from rat liver by two methods. A summary of the purification data is presented in Table 1 . Method 1, i.e. hydroxyapatite, yielded the fraction with the greater specific activity and, accordingly, was employed more frequently.
The rat-liver homogenate was centrifuged at lOOOOOg for 60min. in a no. 30 rotor in a Spinco L-2 ultracentrifuge at 50 to yield the soluble extract without any appreciable loss in enzymic activity. Solid ammonium sulphate was added to the soluble extract to 30% saturation and the suspension was stirred at 4°for lOmin. The suspension was centrifuged at lOOOOg for lOmin. and the precipitate was dissolved in O-OlM-imidazole buffer, pH7-0, which contained 3mM-mercaptoethanol. The ammonium sulphate fraction was dialysed for 4hr. against the imidazole buffermercaptoethanol in a rocking dialyser. The dialysed fraction retained approx. 80% of the original activity and had specific activity 0 34, which was 8-5-fold greater than the original homogenate. A sample of the dialysed fraction (100ml.) was applied to a column of hydroxyapatite, 4cm. x 10cm., which had been equilibrated with 0-05M-phosphate buffer (pH 8 0)-3mM-mercaptoethanol. The column was developed stepwise with increasing concentrations of phosphate buffer (pH 8.0)-3mM-mercaptoethanol. The enzymic activity could be eluted with 0 3M-phosphate. The specific activity of the enzyme increased to 1 82,umoles of product/ 15min./mg. of protein in a yield of 31%.
Solid ammonium sulphate was added to the hydroxyapatite fraction to 30% saturation and the suspension was stirred for 5min. at 5°. The enzyme was sedimented after centrifugation at 100OOg
for lOmin. and was dissolved in 0 05M-tris buffer (pH 9.2)-3mM-mercaptoethanol. The specific activity of the latter ranged from 4'5 to 7-8 with an overall yield of 17% and an overall purification of approx. 140-fold.
A second procedure for concentration of the enzyme was employed in the initial stages of the investigation. The 30% ammonium sulphate fraction (lOml.) was applied to a column of Sephadex G-200, 4-Ocm. x 50cm., which had been equilibrated with 0 05M-tris buffer, pH9-2, that contained 3mm-mercaptoethanol. The enzyme, which was eluted with the void volume after development of the column with this buffer, was concentrated by a second treatment with ammonium sulphate (to 30%). The The pKm has been plotted against the pH and gives an inflexion point at pH9-0 (Fig. 3) . If Km is equal to K, these data may indicate an ionization constant of the group in the enzyme to which the aspartate is bound, the pK. (Dixon & Webb, 1964) .
The possibilities for a group with this pK include: SH-; oc-ammonium; phenolic hydroxyl (tyrosine); E-ammonium (lysine) (Dixon & Webb, 1964) .
Effect of temperature. Aspartate carbamoyltransferase was gradually inactivated at temperatures at and above 500. or Hg2+; at 2mM, Zn2+ inhibited enzymic activity by 87%. The inhibition was relieved by the concomitant incorporation into the reatction medium of mercaptoethanol at 0 6mM. The concentrations of Ag+ and Hg2+ which was necessary for the production of 50% inhibition of enzymic activity were 0-75 and 0-5mM respectively. Agent8 which disrupt hydrogen and hydrophobic bonding. Enzymic activity was also sensitive to sodium lauryl sulphate, urea and dioxan. Over Table 3 . Inhibition of liver a8partate carbamoyltran8fera8e by structural analogueM of L-a8partate
The enzyme source was (NH4)2SO4-treated hydroxyapatite fraction, 22,ug. Carbamoylaspartate was determined by the colorimetric assay. The number of determinations is indicated within the parentheses after the structural analogue; the range of K, is also indicated within parentheses.
L-Aspartate (6) Succinate (4) Maleate (4) Oxaloacetate (3) ,B-erythro-Hydroxy-DL-aspartate (2) f-Benzyl-L-aspartate (2) Km (mM) 3*0 (2-1-3-6) Ki (mM) 3-3 (2.9-5.8) 1-8 (1-6-2-4) 6-8 (5.8-8.0) 2-9 (2-7-3.1) 3*1 (2.9-3.3) Inhibition by 8tructural analogues of a8partate. Enzymic activity was inhibited by the structural analogues of L-aspartate, succinate and maleate, which at 6 and 4mM respectively diminished activity by 50% (Fig. 4) . A number of other analogues proved to be effective inhibitors of aspartate carbamoyltransferase (Table 3 ). The compounds presented in Table 3 were competitive inhibitors (with aspartate) of the enzyme. The most effective of these inhibitors was maleate, which had Ki 1 8mM as compared with Km for aspartate 3O0mM. The least potent was oxaloacetate with Ki 6-9mM. The fl-erythro-hydroxy-DLaspartate, P-benzyl-L-aspartate and succinate possessed a similar K, 3mM.
The compounds which did not inhibit enzymic activity at inhibitor/substrate ratios 20:1 have been tabulated in Table 4 . In this Table are included several analogues of carbamoyl phosphate.
Effects of other 8ubstances. The [14C]aspartate assay was employed to test the efficacy of several compounds as inhibitors of liver aspartate-carbamoyltransferase activity. The ineffective compounds included: EDTA (to 7mM), UTP, CTP, deoxyadenosine or deoxyAMP (at inhibitor/aspartate = 1), CN-or N3-(to 5mM). Deoxyadenosine and deoxyAMP, in agreement with the results of Neumann & Jones (1964) , did inhibit the development of the colour in the colorimetric assay. Pyrimidine ribo-and deoxyribo-nucleosides inhibited enzymic activity slightly only in the presence of high concentrations of L-aspartate, i.e. 14mM.
DISCUSSION
Although aspartate carbamoyltransferase has been extensively purified and crystallized from extracts of de-repressed Ewcherichia coli (Shepherdson & Pardee, 1960) , the enzyme from mammalian sources has only been partially purified from rat liver. The initial observations on the mammalian enzyme were reported by Lowenstein & Cohen (1956) with crude extracts. In view of the importance of this enzyme in the metabolic control of pyrimidine biosynthesis in bacteria, it seemed of importance to obtain comparative data with the mammalian enzyme. The procedure described herein offers a relatively simple means to accomplish this objective.
A comparison of a number of properties of the two enzymes is presented in Table 5 . The Escherichia coli aspartate carbamoyltransferase may be precipitated from a soluble extract by saturation with ammonium sulphate.
The pH optimum for the Eacherichia coli enzyme is markedly influenced by the substrate concentration, i.e. aspartate. At concentrations of aspartate < 5 mM, maximum activity is manifested at pH 6'8; at concentrations > 25 mm, maximum activity may be noted at pH8-2 (Gerhart & Pardee, 1964) . In the bacterial enzyme, the aspartate saturation (Gerhart & Pardee, 1963) . Sigmoidal kinetics, which are reminiscent of the Bohr effect with the haemoglobins, are observed at alkaline pH values (Gerhart & Pardee, 1963) . The mammalian enzyme does not exhibit the -sigmoidal kinetics and, in this respect, behaves like the bacterial monomer. The bacterial enzyme is subject to end-product inhibition by CTP (Gerhart & Pardee, 1962) . The formation of the CTP-bound enzyme apparently favours the less active conformation of aspartate carbamoyltransferase, a concept which has been fully exploited by Changeux (1964) and Monod, Wyman & Changeux (1965) . The pyrimidine end product, however, has little effect upon the liver enzyme although, at high aspartate concentrations, a small inhibition may be observed (Bresnick, 1963) . No inhibition by CTP of enzymic activity has been reported in crude extracts from lettuce seedlings (Neumann & Jones, 1964) or erythrocytes (Curci & Donachie, 1964 ). It appears quite unlikely that the mammalian enzyme is subject to endproduct inhibition, a conclusion which is in substantial agreement with that of Curci & Donachie (1964) .
The liver enzyme, in contrast with the Escherichia coli enzyme, is markedly inhibited by mercurials and by thiol reagents, as first reported by Lowenstein & Cohen' (1956) and confirmed in this paper. The thiol group of the mammalian enzyme is apparently associated with the catalytic activity.
The mammalian enzyme also differs from the bacterial aspartate carbamoyltransferase in the response to maleate (Gerhart & Pardee, 1964) . At concentrations of maleate < 2mm, significant stimulation of enzymic activity may be demonstrated in the latter (Gerhart & Pardee, 1964) , whereas a marked inhibition is observed with the former.
The substrate specificity and inhibition data with the liver enzyme allow one to speculate on the nature of active site, i.e. one of the active sites. The substrate, L-aspartate, apparently interacts in the'chair'formwith aspartate carbamoyltransferase.
This inference is based on Ki for maleate, which is lower than Km for aspartate, and on the finding that fumarate doas not inhibit enzymic activity. Succinate, like aspartate, can exist in the 'chair' form as well as in other configurations, and hence possesses K, similar to Km for aspartate.
The site on the liver aspartate carbamoyltransferase to which carbamoyl phosphate is bound is very specific. Under our conditions, no substitute could be found which would either inhibit carbamoylaspartate formation in the presence of carbamoyl phosphate or would react with aspartate in the absence of carbamoyl phosphate. In addition pyrophosphate, a competitive inhibitor of the latter, with the bacterial aspartate carbamoyltransferase (Kleppe, 1965) exhibits little effect upon enzymic activity at inhibitor/carbamoyl phosphate ratios 40:1. Neither ethyl urethane, in which the phosphate of carbamoyl phosphate is replaced by an ethoxy group, nor acetyl phosphate, in which the amide of carbamoyl phosphate is replaced by a methyl group, can effect any enzymic alteration of aspartate.
The findings clearly demonstrate the differences between the properties of the liver aspartate carbamoyltransferase and the E8cherichia coli enzyme. These differences are attended by the lack of a mechanism for control of enzymic activity in the liver (at least in vitro). If feedback control of pyrimidine biosynthesis does occur in vivo, it does so at a site distinct from aspartate carbamoyltransferase.
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